Clinical Trial: Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07892989) titled 'Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above' on Oct. 19.

Brief Summary: Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled "A Randomized, Blinded, Controlled, Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6052 (Recombinant Herpes Zoster Vaccine (CHO Cell)) Admini...